EQRX Stock Price, EQRx, Inc. Quote, Chart

Market Summary

USD2.34

Market Closed

EQRX Stock Price

View Fullscreen

EQRX RSI Chart

EQRX Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-4.38

Price/Sales (Trailing)

18.81

Price/Free Cashflow

-3.44

EQRX Price/Sales (Trailing)

EQRX Profitability

Return on Equity

-22.23%

Return on Assets

-20.99%

Free Cashflow Yield

-29.06%

EQRX Fundamentals

EQRX Revenue

Revenue (TTM)

60.7M

Rev. Growth (Yr)

100.82%

Rev. Growth (Qtr)

2.6%

EQRX Earnings

Earnings (TTM)

-260.3M

Earnings Growth (Yr)

2.89%

Earnings Growth (Qtr)

-13.26%

Breaking Down EQRX Revenue

Last 7 days

20.5%

Last 30 days

11.3%

Last 90 days

10.8%

Trailing 12 Months

-51.9%

How does EQRX drawdown profile look like?

EQRX Financial Health

Current Ratio

18.78

EQRX Investor Care

Buy Backs (1Y)

0.15%

Diluted EPS (TTM)

-0.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	40.4M	52.4M	60.7M	0
2022	6.6M	12.8M	19.0M	25.1M
2021	181.8K	266.5K	351.3K	436.0K
2020	0	0	0	97.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of EQRx, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 09, 2023	ah equity partners bio ii, l.l.c.	sold	-	-	-5,000,000	-
Nov 09, 2023	borisy alexis	back to issuer	-	-	-18,810,000	executive chairman
Nov 09, 2023	abernethy amy	back to issuer	-	-	-200,000	-
Nov 09, 2023	horning sandra	back to issuer	-	-	-470,250	-
Nov 09, 2023	conde jorge	back to issuer	-	-	-11,433,700	-
Nov 09, 2023	conde jorge	back to issuer	-	-	-5,000,000	-
Nov 09, 2023	conde jorge	back to issuer	-	-	-17,438,500	-
Nov 09, 2023	conde jorge	back to issuer	-	-	-19,192,000	-
Nov 09, 2023	nallicheri melanie	back to issuer	-	-	-3,851,150	chief executive officer
Nov 09, 2023	nallicheri melanie	acquired	1,385,670	2.21	626,999	chief executive officer

Which funds bought or sold EQRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-73,846,900	-	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-2,966,450	-	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	sold off	-100	-353,526	-	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	sold off	-100	-10,000	-	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	sold off	-100	-25,000	-	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	sold off	-100	-241,000	-	-%
Feb 16, 2024	BLUEFIN CAPITAL MANAGEMENT, LLC	sold off	-100	-2,646,760	-	-%
Feb 15, 2024	Legal & General Group Plc	sold off	-100	-435,072	-	-%
Feb 15, 2024	Westchester Capital Management, LLC	sold off	-100	-16,923,100	-	-%
Feb 15, 2024	Virtus ETF Advisers LLC	sold off	-100	-121,299	-	-%

Are Funds Buying or Selling EQRX?

Are funds buying EQRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EQRX

No. of Funds

Unveiling EQRx, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 17, 2023	ah bio fund ii, l.p.	0.0%	0	SC 13D/A
Nov 17, 2023	arch venture fund x, l.p.	-	0	SC 13G/A
Nov 15, 2023	andreessen horowitz fund i, l.p.	0.0%	0	SC 13D/A
Nov 15, 2023	casdin capital, llc	0%	0	SC 13D/A
Feb 09, 2023	vanguard group inc	5.31%	25,952,741	SC 13G
Jan 18, 2023	softbank group corp	4.5%	21,800,000	SC 13D/A
Nov 29, 2022	casdin capital, llc	11.5%	56,297,042	SC 13D/A
Feb 14, 2022	gv 2019, l.p.	9.69%	47,252,687	SC 13G
Feb 14, 2022	citadel advisors llc	0.0%	6	SC 13G/A
Feb 11, 2022	arch venture fund x, l.p.	7.5%	36,335,375	SC 13G

Peers (Alternatives to EQRx, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-2.93%	-28.56%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.14%	-28.32%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	5.64%	-9.07%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-9.46%	-28.45%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-16.55%	-42.15%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-12.14%	49.76%	-6.72	60.35	54.84%	-34.79%
AXSM	3.1B	270.6M	-14.48%	-8.88%	-13.01	11.51	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.72%	-14.74%	-45.89	3.87	40.45%	71.62%
ARWR	2.8B	240.7M	-18.65%	-25.84%	-9.44	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-6.41%	-11.48%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-21.26%	-56.58%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-14.69%	262.26%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-4.49%	-3.41%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	67.92%	36.92%	-0.22	2.14	-13.45%	66.37%

EQRx, Inc. News

Latest updates

EQRx, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	2.6%	16,485,000	16,068,000	15,442,000	12,668,000	8,209,000	4,091,000	182,000	127,667	73,333	19,000	144,000	-
Operating Expenses	10.6%	101,548,000	91,836,000	101,798,000	100,730,000	90,366,000	79,090,000	85,691,000	94,801,000	39,976,000	34,639,000	26,959,000	177,645,000
S&GA Expenses	9.0%	23,404,000	21,476,000	27,277,000	29,232,000	34,095,000	31,792,000	32,263,000	38,585,000	16,176,000	13,223,000	10,282,000	8,562,000
R&D Expenses	-54.7%	19,729,000	43,574,000	70,933,000	71,498,000	56,271,000	47,298,000	53,428,000	56,216,000	23,800,000	21,416,000	16,677,000	169,083,000
EBITDA Margin	-	-	-	-	-	-	-226	-226	-226	-	-	-	-
EBT Margin	-	-	-	-	-	-	-229	-229	-229	-	-	-	-
Net Income	-13.3%	-82,631,000	-72,956,000	-82,551,000	-22,177,000	-85,092,000	-82,546,000	20,726,000	1,224,000	-39,890,000	-34,526,000	-26,817,000	-177,613,000
Net Income Margin	14.5%	-4.29	-5.02	-6.74	-6.72	-7.68	-7.85	-7.93	-229	-711	-938	-1,375	-2,577
Free Cashflow	19.6%	-61,907,000	-77,041,000	-85,990,000	-106,753,000	-62,118,000	-65,579,000	-53,951,000	-80,488,000	-42,015,000	-37,561,000	-23,564,000	-173,261,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2021Q1	2020Q4	2019Q4
Assets	-5.4%	1,240	1,311	1,384	1,455	1,543	1,608	1,674	1,729	554	553	536	518	501	20.00
Current Assets	-3.8%	1,235	1,284	1,355	1,428	1,524	1,588	1,655	1,706	2.00	1.00	0.00	-	492	19.00
Cash Equivalents	27.5%	316	248	368	494	998	864	1,623	1,679	456	500	537	-	490	19.00
Net PPE	-100.0%	-	2.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	-	-	3.00	0.00
Liabilities	10.0%	69.00	63.00	70.00	66.00	143	134	126	215	74.00	81.00	-	50.00	18.00	28.00
Current Liabilities	15.8%	66.00	57.00	60.00	52.00	63.00	55.00	57.00	40.00	2.00	0.00	0.00	0.00	14.00	28.00
Shareholder's Equity	-6.2%	1,171	1,248	1,314	1,389	1,400	1,475	1,549	1,515	456	494	527	0.00	482	-
Retained Earnings	-12.1%	-765	-683	-610	-527	-505	-420	-337	-358	-72.17	-31.84	48.00	-751*	-258	-8.51
Additional Paid-In Capital	0.3%	1,936	1,931	1,924	1,917	1,907	1,897	1,886	1,873	5.00	37.00	0.00	0.00	741	-
Shares Outstanding	0.4%	485	483	481	479	476	472	471	469	321	315	311	-	298	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	19.5%	-61,907	-76,891	-85,546	-105,796	-62,104	-65,430	-53,938	-80,384	-41,966	-37,309	-23,521	-172,243	-53,113	-13,547	-2,603
Share Based Compensation	-28.3%	4,869	6,790	7,592	9,225	9,432	9,988	12,906	22,410	2,016	1,016	784	-	-	-	-
Cashflow From Investing	394.9%	129,874	-44,041	-40,359	-398,417	194,916	-693,763	-13.00	-4,104	-49.00	-252	-43.00	-1,018	-1,173	-711	-78.00
Cashflow From Financing	182.4%	209	74.00	127	327	774	361	-1,323	1,306,560	-1,673	345	71,256	496,919	108,154	88,403	22,003

EQRX Income Statement

2023-09-30

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 19,729	$ 56,271	$ 134,236	$ 156,997
General and administrative	23,404	34,095	72,157	98,150
Restructuring	58,415		88,789
Total operating expenses	101,548	90,366	295,182	255,147
Loss from operations	(101,548)	(90,366)	(295,182)	(255,147)
Other income (expense):
Change in fair value of contingent earn-out liability	(110)	(2,706)	4,556	90,863
Change in fair value of warrant liabilities	2,530	(197)	4,501	4,934
Interest income, net	16,485	8,209	47,995	12,482
Other expense, net	12	(32)	(8)	(44)
Total other income (expense), net	18,917	5,274	57,044	108,235
Net loss	(82,631)	(85,092)	(238,138)	(146,912)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	(14)	33	(3)	49
Unrealized holding gains (losses) on short-term investments	132	370	403	(1,672)
Comprehensive loss, net of tax	(82,513)	(84,689)	(237,738)	(148,535)
Net loss attributable to common stockholders - basic	(82,631)	(85,092)	(238,138)	(146,912)
Net loss attributable to common stockholders - diluted	$ (82,631)	$ (85,092)	$ (238,138)	$ (146,912)
Net income (loss) per share - basic (in dollars per share)	$ (0.17)	$ (0.18)	$ (0.49)	$ (0.31)
Net income (loss) per share - diluted (in dollars per share)	$ (0.17)	$ (0.18)	$ (0.49)	$ (0.31)
Weighted average common shares outstanding - basic (in shares)	484,229,709	475,565,990	482,135,388	473,101,935
Weighted average common shares outstanding - diluted (in shares)	484,229,709	475,565,990	482,135,388	473,101,935

EQRX Balance Sheet

2023-09-30

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 315,676	$ 494,136
Short-term investments	896,624	905,150
Prepaid expenses and other current assets	22,206	28,800
Restricted cash	633
Total current assets	1,235,139	1,428,086
Property and equipment, net		2,627
Restricted cash		633
Right-of-use asset		3,804
Other investments	4,000	4,000
Other non-current assets	1,151	15,866
Total assets	1,240,290	1,455,016
Current liabilities:
Accounts payable	8,103	19,950
Accrued expenses	55,623	29,596
Lease liability, current	2,060	2,370
Total current liabilities	65,786	51,916
Non-current liabilities:
Contingent earn-out liability	2,604	7,160
Warrant liabilities	792	5,293
Lease liability, non-current		1,461
Restricted stock repurchase liability	188	324
Total liabilities	69,370	66,154
Commitments and contingencies (note 13)
Stockholders' equity:
Preferred stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding as of September 30, 2023 and December 31, 2022
Common stock, $0.0001 par value; 1,250,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 537,540,870 and 538,549,210 shares issued as of September 30, 2023 and December 31, 2022, respectively; and 484,965,823 and 478,674,305 shares outstanding at September 30, 2023 and December 31, 2022, respectively	49	49
Additional paid-in capital	1,936,346	1,916,550
Accumulated other comprehensive income (loss)	252	(148)
Accumulated deficit	(765,727)	(527,589)
Total stockholders' equity	1,170,920	1,388,862
Total liabilities and stockholders' equity	$ 1,240,290	$ 1,455,016

About EQRx, Inc.

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

CEO	Ms. Melanie I. Nallicheri
WEBSITE	eqrx.com
INDUSTRY	Biotechnology
EMPLOYEES	362

EQRx, Inc. Frequently Asked Questions

What is the ticker symbol for EQRx, Inc.? What does EQRX stand for in stocks?

EQRX is the stock ticker symbol of EQRx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of EQRx, Inc. (EQRX)?

As of Thu Nov 09 2023, market cap of EQRx, Inc. is 1.14 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EQRX stock?

You can check EQRX's fair value in chart for subscribers.

What is the fair value of EQRX stock?

You can check EQRX's fair value in chart for subscribers. The fair value of EQRx, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of EQRx, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EQRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is EQRx, Inc. a good stock to buy?

The fair value guage provides a quick view whether EQRX is over valued or under valued. Whether EQRx, Inc. is cheap or expensive depends on the assumptions which impact EQRx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EQRX.

What is EQRx, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Nov 09 2023, EQRX's PE ratio (Price to Earnings) is -4.38 and Price to Sales (PS) ratio is 18.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EQRX PE ratio will change depending on the future growth rate expectations of investors.